류마티스 관절염의 약물치료(I): NSAID, DMARD, 스테로이드 = Medical treatment of rheumatoid arthritis (I): Nonsteroidal anti-inflammatory drugs, disease modifying antirheumatic drugs and glucocorticoids

다국어 초록 (Multilingual Abstract)

The medical treatment of rheumatoid arthritis has been dramatically improved with the advances of newer disease-modifying antirheumatic drugs (DMARDs) and biologic agents during previous decades. To prevent joint damage, it is essential to start DMARD treatment early, especially within the first 3 months after diagnosis. Tight control of disease activity, and the thorough monitoring of the treatment’s efficacy and the side effects of medications are also important.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are usually used to control pain and swelling of the joints. However, these drugs cannot alter the disease course of rheumatoid arthritis. It is therefore necessary to introduce DMARDs at the beginning of treatment, and, after achieving the effect of DMARDs, NSAIDs should be tapered as soon as possible. The main treatment should be DMARDs, which must be used wisely and appropriately. It is also important to adjust DMARD therapy during the course of treatment according to disease activity. Glucocorticoids have potent anti-inflammatory effects and can control inflammation dramatically. However,because of the diverse and serious side effects of glucocorticoids, the usage of glucocorticoids should be limited to low-dose oral therapy or intra-articular injection, unless otherwise indicated. Along with biologics, there are now various weapons available against rheumatoid arthritis, and it can be treated much more effectively than before.

참고문헌 (Reference)

1 Kremer JM, "Use of methotrexate in the treatment of rheumatoid arthritis"

2 Small RE, "Use of glucocorticoids in the treatment of rheumatoid arthritis"

3 Schur PH, "Treatment of early, moderately active rheumatoid arthritis in adults"

4 Bathon JM, "The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: Where the rubber meets the road" 59 : 757-759, 2008

5 Hochberg MC, "Rheumatology. 4th ed in Other drugs in rheumatic disease" Mosby 487-493, 2008

6 Hochberg MC, "Rheumatology. 4th ed in Disease-modifying antirheumatic drugs 4:leflunomide" Mosby 461-469, 2008

7 Hochberg MC, "Rheumatology. 4th ed in Disease-modifying antirheumatic drugs 2:sulfasalazine" Mosby 437-447, 2008

8 Wilske KR, "Remodeling the Pyramid-a Concept Whose Time Has Come" 16 : 565-567, 1989

9 Klippel JH, "Primer on the Rheumatic Diseases. 13th ed in Nonsteroidal anti-inflammatory drugs" Arthritis Foundation 634-643, 2008

10 Nieman LK, "Pharmacologic use of glucocorticoids"

11 Deighton C, "Management of rheumatoid arthritis: summary of NICE guidance" 338 : b702-, 2009

12 Fauci A, "Harrison’s Principles of Internal Medicine(Korean Language Edition). 17th ed in Rheumatoid arthritis" McGraw-Hill 2506-2516, 2009

13 American College of Rheumatology Ad Hoc Committee on Clinical Guidelines, "Guidelines for the management of rheumatoid arthritis" 39 : 713-722, 1996

14 American College of Rheumatology Ad Hoc Committee On Clinical Guidelines, "Guidelines for the management of rheumatoid arthritis" 46 : 328-346, 2002

15 Hoes JN, "EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases" 66 : 1560-1567, 2007

16 Chan FK, "Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomized trial" 376 : 173-179, 2010

17 Hawkey CJ, "COX-2 inhibitors" 353 : 307-314, 1999

18 Tannenbaum H, "An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference" 33 : 140-157, 2006

19 Saag KG, "American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis" 59 : 762-768, 2008